PPARA and in situ carcinoma: To test if PPAR-α is involved in the CR mechanism of renal protection from cisplatin nephrotoxicity, we treated mice on CR with MK886, a PPAR-α antagonist (Kehrer et al., 2001), and compared these mice with the CIS and control groups.